Epilepsy & Seizures

Epidiolex for Dravet Syndrome and Lennox Gastaut Syndrome Available for Prescription

Thursday, November 01, 2018—Pharmaceutical grade cannabidiol (CBD) (Epidiolex; Greenwich Biosciences, Carlsbad, CA), approved by the FDA for treatment of patients age 2 and up with Lennox-Gastaut Syndrom…

Disease-Modifying Treatment for Dravet Syndrome on the Horizon

Friday, October 05, 2018—A potentially disease-modifying therapy for Dravet syndrome (DS) being developed by Stoke Therapeutics (Bedford, MA) uses targeted augmentation of nuclear gene output (TANGO) …

Perampanel Now Approved by FDA for Patients With Epilepsy as Young as 4 Years

Monday, October 01, 2018—The Food and Drug Administration (FDA) has approved perampanel (Fycompa; Eisai, Woodcliff Lake, NJ) for use in children age 4 to 12 years. Before this decision, perampanel was…

Cannibidiol Rescheduling Clears Way for Distribution of FDA-Approved Cannabis-Derived Treatment for Dravet and Lennox-Gastaut Syndromes

Friday, September 28, 2018—The FDA-approved formulation of cannabidiol (CBD)(Epidiolex; GW Pharma, Carlsbad, CA) has been rescheduled by the Drug Enforcement Agency (DEA), clearing the way for marketing…

More and More Treatments: Are We There Yet?

Maromi Nei, MD

October 2018—New treatments—from cannabinoids to deep brain stimulation—may help meet the needs of still too many patients with uncontrolled seizures.

Hometown Highlights: Introducing Hometown Highlights

Stephen M. Gollomp, MD

October 2018—In this new column, we feature content from presenters at the 2018-2019 Philadelphia Neurological Society meetings.

Surgical Management of Intractable Epilepsy

Joon Y. Kang, MD

October 2018—Neurosurgical techniques are effective and underutilized for patients with drug-resistant epilepsy.

Neuromodulation and Epilepsy

Ahmad Soltani, MD; Isha Sharan; and Ashwini Sharan, MD

October 2018—From the vagal nerve to the deep brain, neuromodulation provides another treatment option for patients with epilepsy.